Varian, Inc. Reports Fourth Quarter 20...(Impairment of private company eq...),Health

Date:11/4/2009

Impairment of private company equity investment - - - 0.06 Restructuring and other related costs 0.01 0.03 0.22 0.12 ------- ------- ------- ------- As adjusted $ 0.40 $ 0.78 $ 2.01 $ 2.62 ======= ======= ======= ======= Free Cash Flow U.S. GAAP as reported - Net cash provided by operating activities $33,558 $19,396 $112,887 $79,021 Adjustments: Proceeds from sale of property, plant and equipment 344 470 6,454 1,735 Purchase of property, plant and equipment (4,245) (7,286) (25,073) (23,960) ------ ------ ------- ------- As adjusted - Free Cash Flow $29,657 $12,580 $94,268 $56,796 ======= ======= ======= =======

                    VARIAN, INC. AND SUBSIDIARY COMPANIES
            RECONCILIATION OF GAAP TO ADJUSTED RESULTS - ACTUAL
                     UNAUDITED RESULTS OF OPERATIONS
                    (In thousands, except margin data)

             Fourth Quarter FY 2009 and Fourth Quarter FY 2008
                                   and
                  Full Year FY 2009 and Full Year FY 2008

                                 Fiscal Quarter Ended    Fiscal Year Ended
                                 --------------------    -----------------
                                  October 2, October 3, October 2, October 3,
                                      2009      2008      2009      2008
                                     -------   -------   -------   -------
    TOTAL COMPANY (Continued)
    -------------------------
    Operating Earnings
      U.S. GAAP as reported     $5,104    $32,859   
'/>"/>
SOURCE  Varian, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Related medicine technology :

1. Varian, Inc. to Release Fourth Quarter and Full Fiscal Year 2009 Financial Results
2. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
3. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
4. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
5. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
6. Cambrex Reports Third Quarter 2009 Results
7. Regeneron Reports Third Quarter 2009 Financial and Operating Results
8. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
9. Uroplasty Reports Results for Second Quarter FY2010
10. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
11. Mettler-Toledo International Inc. Reports Third Quarter 2009 Results